Revolution Cancer International Molecular Tumor Board
Revolution Cancer International Molecular Tumor Board
  • Home
  • About Us
  • Contact Us
  • More
    • Home
    • About Us
    • Contact Us
  • Home
  • About Us
  • Contact Us

PLAYING CHESS AGAINST CANCER

PLAYING CHESS AGAINST CANCERPLAYING CHESS AGAINST CANCERPLAYING CHESS AGAINST CANCER
Revolution Cancer International Molecular Tumor Board (CLICK HERE TO JOIN)

PLAYING CHESS AGAINST CANCER

PLAYING CHESS AGAINST CANCERPLAYING CHESS AGAINST CANCERPLAYING CHESS AGAINST CANCER
Revolution Cancer International Molecular Tumor Board (CLICK HERE TO JOIN)

About THE RCIMTB

The Revolution Cancer International Molecular Tumor Board (RCIMTB) was started to transform the approach to precision medicine in cancer patients.  Bridging the worlds of drug discovery and target identification, clinical trials, precision medicine, AI/ML, and cancer care, the RCIMTB will uniquely epitomize translational medicine.  


The RCIMTB isn't interested in incremental change.  It wholeheartedly believes the fundamental metric is that every patient must receive the care one would want for a father, mother, brother, sister, or child.  Accordingly, it will challenge existing paradigms as it is unapologetically forward-thinking, and fixated on "truly moving the needle" for cancer patients.


The RCIMTB is open to all, including drug developers, patients, clinicians, pharmaceutical and precision medicine employees, etc.  It is predicated on audience participation as audience members are encouraged to speak about drugs and clinical trials they have related to patients being presented.  


The RCIMTB isn't being monetized in any capacity.  It is intentionally free of outside influence, and is interested only in revolutionizing the lives of cancer patients.


If you are a drug developer, clinician, variant scientist, pharmaceutical employee, etc, who wishes to be a permanent RCIMTB panel member please contact us through the link on this page.  We welcome all individuals in this regard. 

Catch up on revolution cancer Tumor boards

October 8, 2022, Revolution Cancer International Molecular Tumor Board - Merck, MSI-High CRC, NTRK

 In the October 8, 2022, the audience was treated to an extensive MSI-high stage 4 colorectal cancer discussion.  

Four stage 4 MSI-high colon cancer patients were presented.  This included an extensive discussion of NTRK fusions and homologous recombination deficiency in colorectal cancer.  Immunotherapy resistance in MSI-high patients was highlighted.    


The Merck pipeline was presented in detail, including MK-0482, nemtabrutinib, quavonlimab, zilovertamab vedotin, keytruda, favezelimab, MK-4830, MK-5890, MK-2870, MK-5684, ladiratuzumab vedotin, Welireg, miransertib, tucatinib, lynparza, vibostolimab, lenvatinib, and 937. 


During this there was a conversation of BTK inhibitors, belzutifan, ipilimumab, relatlimab, ipatasertib, capivasertib, etc.    


All approved stage 4 colorectal cancer treatments were presented.  Ongoing stage 4 CRC trials were highlighted, as were unmet needs and trial/study opportunities in stage 4 CRC.
 

September 24, 2022, Revolution Cancer International Molecular Tumor Board- NOVARTIS, MET, MDM2, MSI

   In the September 24, 2022, the audience was treated to a wondrous MET exon 14 (METex14) skipping mutation discussion, including a real-world case discussion of a stage 4 non-small cell lung cancer  (NSCLC) patient with METex14, mdm2 overexpression, and SMARCA4 deficiency.

MET inhibitor resistance was discussed in profound detail.   

 In addition, a MSI-high stage 4 prostate cancer patient was presented.  

Emphasis on immunotherapy and discussion of Pluvicto highlighted the discussion. 

Novel clinical trial paradigms were discussed.  

The Novartis pipeline was highlighted as their entire hematology/medical oncology drug development program was elucidated in a way few others are capable of.    

September 10, 2022, Revolution Cancer International Molecular Tumor Board- HUTCHMED, ALK, MET, HSP90

  In the September 10, 2022, RCIMTB the audience was treated to a wondrous ALK fusion discussion, including a real-world case discussion of a stage 4 non-small cell lung cancer  (NSCLC) patient with 2 ALK fusions.  


The HUTCHMED pipeline was highlighted as savolitinib, surufatinib, fruquintinib, tazemetostat, sovleplenib, amdizalisib, HMPL-453, HPML-306, HPBL-295, HMPL-760, HMPL-653, and HMPL-A83 were discussed.  


During this there was a conversation of approved BTK, IDH 1/2, FGFR 1/2/3, and SYK inhibitors.  


We did speak of the toxicity concerns regarding PI3K delta inhibitors, such as amdizalisib, including how idelalisib, umbralisib, and duvelisib were pulled off the market.  


We talked about how CD47 inhibitors have become much maligned.  We reviewed the new fruquintinib data that may lead to its approval in stage 4 colorectal cancer.    


During the patient case, we talked about ALK resistance mechanism and MET amplification in this setting.  


We discussed the use of combination therapy and focused on HSP90 inhibitors.    


Due to time constraints we pushed our incredible MET Ex14 case and discussion to the September 24, 2022, tumor board..    


An incredible analysis of the stage 4 double ALK FUSION stage 4 non-small cell lung cancer (NSCLC) patient was performed in the context of the COMET algorithm and treatment cartography.  


All presently FDA-approved non-small cell lung cancer treatments were discussed, including the data that led to their approval.    


Clinical trials in the stage 4 ALK fusion non-small cell lung cancer space were depicted.   

August 27, 2022, Revolution Cancer International Molecular Tumor Board -SMARCA4 deconstructed, NSCLC

 In the August 27, 2022, the audience was treated to the PREMIER SMARCA4 discussion on the planet, including a mind blowing discussion of 2 patients with stage 4, SMARCA4 deficient non-small cell lung cancers.   


The Glasko-Smith-Klein (GSK) pipeline was highlighted, as momelotinib, niraparib, dostarlimab, cobolimab, etc., were discussed.  This included their STING agonist, LAG3  inhibitor, etc.    We reviewed the new niraparib neoadjuvant breast cancer data.


  MTAP loss was featured as we talked about ways to target it.  Novel clinical trials were proposed and SMARCA4 unmet needs were elucidated.  


An incredible analysis of the stage 4 SMARCA4 deficient, MTAP loss, and TMB-high, non-small cell lung cancer (NSCLC) patient was performed in the context of the COMET algorithm and treatment cartography.  


All presently FDA-approved non-small cell lung cancer treatments were discussed, including the data that led to their approval.    


Clinical trials in the stage 4 SMARCA 4 deficient and MTAP loss non-small cell lung cancer space were depicted.    



August 13, 2022, Revolution Cancer International Molecular Tumor Board (KRAS dismantled)

Overview

KRAS as never before

Revolution Medicines Pipeline

Two Stage 4 Non-small cell lung cacner cases


Includes

Cancer Clarity Unmet Needs for Drug Developers

Cancer Clarity NOVEL Clinical Trials We'd Like to See


July 30, 2022, Revolution Cancer International Molecular Tumor Board (p53 under the microscope)

PMV Pharma Pipeline

Extensive Stage Small Lung Cancer Case

NINE Stage 4 Hepatocellular Cancer Cases


Includes

Cancer Clarity Unmet Needs for Drug Developers

Cancer Clarity NOVEL Clinical Trials We'd Like to See

July 16, 2022, Revolution Cancer International Molecular Tumor Board (HER2 and lowHER2, HER3, TROP2, AKT1, PIK3CA)

Overview

Daiichi Sankyo Pipeline

Breast Cancer Case


Includes

Cancer Clarity Unmet Needs for Drug Developers

Cancer Clarity NOVEL Clinical Trials We'd Like to See


"The insider's guide to translational medicine" series

publically available Free Downloads

These slides depict the current cellular therapy and gene therapy landscapes

WFS - Cell & Gene Therapy Bullseyes (March 2022) (1) (pdf)Download

Connect With Us

Subscribe TO Make Sure you DON't MIss a Single RCIMTB

Our Partners

Copyright © 2022 Revolution Cancer International Molecular Tumor Board - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept